You are here:

Archived: bevacizumab (Avastin)

Advice

following a re-submission considered under the end of life /orphan medicine process

bevacizumab (Avastin®) is not recommended for use within NHS Scotland.

Indication under review: in combination with carboplatin and paclitaxel, for the front-line treatment of advanced (International Federation of Gynaecology and Obstetrics [FIGO] stages III B, III C and IV) epithelial ovarian, fallopian tube, or primary peritoneal cancer.

Addition of bevacizumab to standard chemotherapy with carboplatin and paclitaxel increased progression-free survival and, in women with stage III and residual disease after surgical debulking or stage IV disease, it increased overall survival. 

The submitting company’s justification of the treatment’s cost in relation to its health benefits was not sufficient and in addition the company did not present a sufficiently robust economic analysis to gain acceptance by SMC.

This advice takes account of the views from a Patient and Clinician Engagement (PACE) meeting.

Drug Details

Drug Name: bevacizumab (Avastin)
SMC Drug ID: 806/12
Manufacturer: Roche
Indication: In combination with carboplatin and paclitaxel, for the front-line treatment of advanced (International Federation of Gynaecology and Obstetrics [FIGO] stages III B, III C and IV) epithelial ovarian, fallopian tube, or primary peritoneal cancer.
BNF Category:
Sub Category: 8.1 Cytotoxic drugs
Submission Type: Resubmission
Status: Not Recommended
Date Advice Published: 12 January 2015

Current Advice

Resubmission 9 November 2015

Archived Advice

Full submission 8 October 2012

Back